| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3997821 | Surgical Oncology | 2012 | 8 Pages |
Abstract
Advanced gastric cancer carries a very poor prognosis when the tumor becomes unresectable. Even with the best currently available chemotherapy regimens the survival rate remains dismal. A recent breakthrough in the treatment paradigm has been the approval of trastuzumab, a monoclonal antibody, in HER2-positive metastatic gastric cancer. A large number of trials are underway using dendritic cells (DCs) in a number of human malignancies and do show a ray of hope in management of these patients. This review attempts to summarize tumor immunology and the current data regarding use of DCs in gastric cancer therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mallika Tewari, Shipra Sahai, Raghvendra R. Mishra, Sunit K. Shukla, Hari S. Shukla,